search
Back to results

Efficiency of Presurgical Basal Cell Carcinoma Margin Mapping

Primary Purpose

Carcinoma, Basal Cell

Status
Terminated
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
OCT Mapped
Sponsored by
Michelson Diagnostics Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Carcinoma, Basal Cell

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Patients with biopsy-proven BCCs who have been referred for MMS

Exclusion Criteria:

  • Patients with BCCs larger than 6 cm2

Sites / Locations

  • SkinCare Network

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

OCT Mapped arm

Control arm

Arm Description

OCT is used to map the tumour margins as the first stage MMS estimate

Standard MMS is performed

Outcomes

Primary Outcome Measures

Average number of Mohs stages
Is the average number of Mohs stages < 1.4 with a 95% confidence level. (P < 0.025)

Secondary Outcome Measures

Size of the surgical defect
Validate that the reduction in MMS stages by use of OCT mapping does not result in an increase in the size of the surgical defect
Average time taken to perform OCT margin mapping
Show that the average time taken to perform OCT margin mapping is < 5 minutes for lesions of area < 2 cm2

Full Information

First Posted
January 29, 2018
Last Updated
January 24, 2020
Sponsor
Michelson Diagnostics Ltd.
Collaborators
Skin Care Network Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT03420846
Brief Title
Efficiency of Presurgical Basal Cell Carcinoma Margin Mapping
Official Title
Efficiency of Presurgical Basal Cell Carcinoma Margin Mapping Using Optical Coherence Tomography
Study Type
Interventional

2. Study Status

Record Verification Date
January 2020
Overall Recruitment Status
Terminated
Why Stopped
Funding exhausted. Sufficient data already collected.
Study Start Date
July 1, 2018 (Actual)
Primary Completion Date
September 1, 2019 (Actual)
Study Completion Date
September 1, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Michelson Diagnostics Ltd.
Collaborators
Skin Care Network Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This Interventional Randomised Controlled study is intended to establish that presurgical margin mapping of BCCs with OCT results in a reduction of the number of MMS surgery stages without adversely impacting clinical outcome, resulting in shorter patient stays and more efficient use of surgical and operating room resources.
Detailed Description
Basal Cell Carcinoma (BCC) is the most common malignancy in humans. Its incidence is continuously increasing. The head and neck areas are most commonly affected due to their increased lifetime exposure to sun compared to other body parts. BCC is often treated by surgical excision which has high cure rate compared to other treatment modalities, but leaves a visible scar which can affect the quality of life of the patient, depending on the location and size of the excision. Mohs Micrographic Surgery (MMS) was developed to minimize the size of the surgical excision whilst maintaining very high cure rate. The main drawback of MMS is that repeated surgery procedures are usually required to eliminate all of the tumour using specialist resources located at the clinic. Optical Coherence Tomography (OCT) allows non-invasive in-vivo imaging of superficial skin lesions. It is in routine clinical use for diagnosis of BCCs, and the diagnostic sensitivity and specificity is well established in published multi-centre trials. A further potential application of OCT is the pre-surgical mapping of the lateral margins of BCC. If the margins of a BCC were accurately known prior to commencing an MMS treatment, the treatment could be performed much more quickly, resulting in shorter patient stays and more efficient use of surgical and operating room resources. Previously published research has already shown that OCT mapping of BCC margins is more accurate than clinical assessment; the objective of the present study is to demonstrate that pre-surgical mapping of BCC margins with OCT is also more efficient.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Carcinoma, Basal Cell

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Participants are randomly assigned to two arms. Participants in the first arm receive Mohs surgery using OCT mapping to delineate tumor margins. Participants in the Control Arm receive Mohs surgery using clinical estimation of tumor margins (ie. standard care) The average number of Mohs surgery cycles will be compared for the two arms.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
86 (Actual)

8. Arms, Groups, and Interventions

Arm Title
OCT Mapped arm
Arm Type
Experimental
Arm Description
OCT is used to map the tumour margins as the first stage MMS estimate
Arm Title
Control arm
Arm Type
No Intervention
Arm Description
Standard MMS is performed
Intervention Type
Other
Intervention Name(s)
OCT Mapped
Intervention Description
Presurgical mapping of Basal Cell Carcinoma margins
Primary Outcome Measure Information:
Title
Average number of Mohs stages
Description
Is the average number of Mohs stages < 1.4 with a 95% confidence level. (P < 0.025)
Time Frame
1 day
Secondary Outcome Measure Information:
Title
Size of the surgical defect
Description
Validate that the reduction in MMS stages by use of OCT mapping does not result in an increase in the size of the surgical defect
Time Frame
1 day
Title
Average time taken to perform OCT margin mapping
Description
Show that the average time taken to perform OCT margin mapping is < 5 minutes for lesions of area < 2 cm2
Time Frame
1 day

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Patients with biopsy-proven BCCs who have been referred for MMS Exclusion Criteria: Patients with BCCs larger than 6 cm2
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Howard Stevens
Organizational Affiliation
Skin Care Network Ltd.
Official's Role
Principal Investigator
Facility Information:
Facility Name
SkinCare Network
City
London
ZIP/Postal Code
SW10 9PJ
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Efficiency of Presurgical Basal Cell Carcinoma Margin Mapping

We'll reach out to this number within 24 hrs